Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
A0A1B0GUS4
UPID:
UB2L5_HUMAN
Alternative names:
Ubiquitin-protein ligase L5
Alternative UPACC:
A0A1B0GUS4
Background:
Ubiquitin-conjugating enzyme E2 L5, also known as Ubiquitin-protein ligase L5, plays a pivotal role in protein degradation pathways. It catalyzes the covalent attachment of ubiquitin to other proteins, a critical process in cellular regulation and homeostasis.
Therapeutic significance:
Understanding the role of Ubiquitin-conjugating enzyme E2 L5 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways highlights its importance in maintaining cellular health and presents an opportunity for targeted drug discovery.